IPO
-
-
-
-
-
-
-
Neothetics (NEOT) Says Phase 2 Proof-of-Concept Study of LIPO-202 Didn't Demonstrate Improvement on Any Efficacy Measurements
-
-
-
-
-
-
-
Unusual 11 Mid-Day Movers 12/15: (BSI) (LL) (CFRX) Higher; (NEOT) (BPMX) (NRX) Lower
-
-
-
-
-
-
-
Neothetics (NEOT) Updates Outlook on Release of Top-Line Data for Two LIPO-202 Phase 3s
-
-
-
-
-
-
-
Neothetics Reports Fourth Quarter and Full Year 2014 Financial Results
-
-
-
-
-
122,962 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

